Pay to Marwadi

Company Profile

SUVEN PHARMACEUTICALS LTD.

NSE : SUVENPHARBSE : 543064ISIN CODE : INE03QK01018Industry : Pharmaceuticals & DrugsHouse : Private
BSE477.403.2 (+0.67 % )
PREV CLOSE (Rs.) 474.20
OPEN PRICE (Rs.) 474.85
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 12915
TODAY'S LOW / HIGH (Rs.)472.50 483.00
52 WK LOW / HIGH (Rs.)375 520.35
NSE477.65 3.45 (+0.73 % )
PREV CLOSE(Rs.) 474.20
OPEN PRICE (Rs.) 474.90
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 477.65 (8 )
VOLUME 483119
TODAY'S LOW / HIGH(Rs.) 472.35 483.25
52 WK LOW / HIGH (Rs.)390.5 520

Company Profile

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 1.05
TTM EPS (Rs.) 16.99
P/E Ratio 28.09
Book Value (Rs.) 68.72
Face Value (Rs.) 1
MCap (Rs. in Mn) 121529.31
Price/Earning (TTM) 25.56
Price/Sales (TTM) 9.14
Price/Book (MRQ) 6.95
PAT Margin (%) 42.24
ROCE (%) 51.79
Incorporation Year : 2018

Management Info :

JV Ramudu - Chairman Venkateswarlu Jasti - Managing Director

Registered Office :

Address : #8-2-334 I, S D E Serene Chambers,3rd Floor Road No. 5,Avenue 7, Banjara Hills ,
Hyderabad,
Telangana-500034

Phone : 040 - 2354 9414 / 3311 / 3315

Website : www.suvenpharm.com

Registrar's Details : K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE
NEWS More
02Jun06-02-2023$Suven Pharmaceuticals informs about earnings call transcript Suven Pharmaceuticals inform
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Suven Pharmaceuticals has informed that it enclosed the transcript of the earnings conference call for the quarter and year ended March 31, 2023 conducted after the meeting of Board of Directors held on May 25, 2023. The above information has been uploaded on the Company's website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-release 

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 read with Para A of Part A of Schedul..
21Apr04-21-2023$CCI approves acquisition of up to 76.10% of voting share capital of Suven by Berhyanda CCI approves acquisition of

The Competition Commission of India (CCI) has approved the acquisition of up to 76.10% of the voting share capital of Suven Pharmaceuticals by Berhyanda.

The proposed combination relates to acquisition by Berhyanda (Acquirer) for up to 76.10% of the voting share capital of Suven Pharmaceuticals (Target), by way of a share purchase agreement dated December 26, 2022 and pursuant to the mandatory open offer in compliance with the Securities and Exchange Board of India (SEBI) (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The Acquirer is the wholly owned subsidiary of Berhyanda Midco, i.e., in turn the wholly owned subsidiary of Jusmiral Midco, which is collectively controlled by the Advent International GPE IX Funds and the Advent International GPE X Funds, which are ultimately managed by Advent International Corporation.

Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

The Competition Commission of India (CCI) has approved the acqu..
18Mar03-18-2023$Suven Pharmaceuticals informs about loss of share certificate Suven Pharmaceuticals inform

Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Suven Pharmaceuticals has informed that the Company has received intimation from shareholder of the Company, regarding loss of share certificate(s) as details enclosed. An email request received from Shareholder is enclosed. The Company is in process of issuing ‘Letter of Confirmation’ in lieu of the original share certificate(s), after completion of required formalities.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 39(3) of SEBI (Listing Obligations and D..
31Jan01-31-2023$Suven Pharmaceuticals informs about conference call for investors Suven Pharmaceuticals inform

Suven Pharmaceuticals has informed that it enclosed an invitation for conducting the conference call for investors on Tuesday, February 7, 2023 at 12:00 Noon IST to discuss the Un-Audited Financial Results for the Q3 & 9M FY23, to be declared on February 6, 2023.

The above information is a part of company’s filings submitted to BSE.

Suven Pharmaceuticals has informed that it enclosed an invitati..
30Jan01-30-2023$Suven Pharmaceuticals informs about board meeting Suven Pharmaceuticals inform
Suven Pharmaceuticals has informed that a Meeting of the Board of Directors of the Company will be held on Monday, the February 6, 2023 at 11:30 am at the Registered Office, SDE Serene Chambers, 3rd Floor, Road No. 5, Banjara Hills, Hyderabad - 500034 of the Company, to consider and approve the following matter(s): To consider and approve the Un-Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the third quarter and nine months ended December 31, 2022 and related matters. Further informed that, Trading Window for dealing in the securities of the company is already closed from 01st January, 2023 as per PIT Code of the Company. Trading window will be opened from 10th February, 2023. 

The above information is a part of company’s filings submitted to BSE.

Suven Pharmaceuticals has informed that a Meeting of the Board..
Financials More
Rs. in Millions
QTR Mar 23 ANNUAL 23
Net Profit1301.64326.02
Gross Profit 1724.64 5793.93
Operating Profit 1853.816276.3
Net Sales 3643.913300.8
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 21918.45 (1.49%)
M.Cap ( in Cr)
46575.18
Sanofi India (BSE)
 7000.60 (2.27%)
M.Cap ( in Cr)
16122.82
Mankind Pharma (BSE)
 1466.05 (4.86%)
M.Cap ( in Cr)
58728.27
Neuland Laboratories (BSE)
 2802.55 (2.42%)
M.Cap ( in Cr)
3595.64
Glaxosmithkline Phar (BSE)
 1389.85 (4.71%)
M.Cap ( in Cr)
23544.90
Shareholding Pattern More
MUTUAL FUNDS/UTI 8.56 %
PROMOTERS 60.01 %
FI/BANKS/INSURANCE 2.26 %
NON-INSTITUTION 19.09 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS More
F & O Quotes